Health brief
Modernizing Rehabilitation and Redefining Alzheimer's Care
Israel revamps its military rehab system to handle a surge of wounded soldiers as a local biotech firm advances a novel brain-protective immunotherapy.
Health
Israel's massive NIS 2B rehabilitation overhaul treats the wartime mental health crisis as a permanent structural challenge — forcing a long-delayed modernization of the state's veteran safety net.
BackgroundIsrael's military rehabilitation system provides long-term medical, psychological, and financial support to wounded soldiers. Before the current conflict, the department operated under bureaucratic Defense Ministry structures that critics argued were chronically underfunded and ill-equipped for large-scale crises.
- The reform designates mental health as a primary focus, establishing combat-related PTSD as its own distinct legal and medical category to accelerate claims processing.
- More than 65% of newly registered wounded soldiers present with psychological or emotional trauma, creating a long-term care demand that local clinics lack the immediate staff to handle.
- The plan expands administrative staffing and assigns dedicated case managers to each veteran, aiming to eliminate the bureaucratic bottlenecks that previously delayed critical treatments.
Health
ImmunoBrain's positive safety trial validates a novel immune-boosting approach to Alzheimer's — shifting the therapeutic focus from direct plaque clearance to restoring systemic brain-protective mechanisms.
BackgroundMost traditional Alzheimer's drugs target and attempt to clear toxic amyloid plaques directly, a strategy that has yielded limited clinical improvements for patients. ImmunoBrain's approach instead focuses on harnessing the body's systemic immune system to clear brain inflammation and preserve cognitive function.
- The clinical trial evaluated IBC-Ab002, an engineered anti-PD-L1 antibody that stimulates immune cells to cross the blood-brain barrier and target disease-damaged regions.
- Forty patients participated across eleven global medical centers, including five active clinical sites in Israel, ensuring local researchers remain at the forefront of the trial.
- The successful safety profile clears the path for larger Phase 2 clinical trials, which will focus on measuring the drug's effectiveness in slowing cognitive decline.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.